Business Wire: August 18, 2016 – GREENVILLE, NC, U.S.A. – Mayne Pharma (ASX: MYX) is pleased to announce it has acquired a portfolio of on-market dermatology foam assets from GSK for US$50.1 million. The foam assets include U.S. rights to Fabior and Sorilux, Canadian rights to Luxiq® and Olux-E® ,…
